ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1766

COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 2081

COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1961

COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 2084

COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2147

Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 1971

Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1938

Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 2053

Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1723

CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 2149

Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 2150

Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 1748

Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 1717

Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1916

Defining Early-stage Knee Osteoarthritis: A Scoping Review

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 2152

Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster III: PsA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].